Meteorin-like levels are associated with active brown adipose tissue in early infancy.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 02 01 2023
accepted: 20 02 2023
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 22 3 2023
Statut: epublish

Résumé

Meteorin-like (METRNL) is a hormonal factor released by several tissues, including thermogenically active brown and beige adipose tissues. It exerts multiple beneficial effects on metabolic and cardiovascular systems in experimental models. However, the potential role of METRNL as brown adipokine in humans has not been investigated previously, particularly in relation to the metabolic adaptations taking place in early life, when brown adipose tissue (BAT) is particularly abundant. METRNL levels, as well as body composition (DXA) and circulating endocrine-metabolic variables, were assessed longitudinally in a cohort of infants at birth, and at ages 4 and 12 months. BAT activity was measured by infrared thermography at age 12 months. METRNL levels were also determined cross-sectionally in adults; Serum METRNL levels were high at birth and declined across the first year of life albeit remaining higher than in adulthood. At age 4 and 12 months, METRNL levels correlated positively with circulating C-X-C motif chemokine ligand 14 (CXCL14), a chemokine released by thermogenically active BAT, but not with parameters of adiposity or metabolic status. METRNL levels also correlated positively with infrared thermography-estimated posterior-cervical BAT activity in girls aged 12 months. Gene expression analysis indicated high levels of Circulating METRNL levels are high in the first year of life and correlate with indices of BAT activity and with levels of an established brown adipokine such as CXCL14. These data, in addition with the high expression of

Identifiants

pubmed: 36936161
doi: 10.3389/fendo.2023.1136245
pmc: PMC10018039
doi:

Substances chimiques

Chemokines, CXC 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1136245

Informations de copyright

Copyright © 2023 Garcia-Beltran, Navarro-Gascon, López-Bermejo, Quesada-López, de Zegher, Ibáñez and Villarroya.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Muscle Nerve. 2005 Oct;32(4):483-91
pubmed: 15962335
Sci Rep. 2019 Apr 9;9(1):5823
pubmed: 30967578
Diabetes. 2015 Dec;64(12):4011-22
pubmed: 26307585
J Exp Med. 2021 May 3;218(5):
pubmed: 33635944
Metabolism. 2014 Mar;63(3):312-7
pubmed: 24369918
J Sport Health Sci. 2018 Apr;7(2):191-196
pubmed: 30356443
Clin Immunol. 2015 Feb;156(2):119-27
pubmed: 25486603
Diabetes. 2017 Mar;66(3):779-784
pubmed: 27986832
Int J Obes Relat Metab Disord. 2001 Jan;25(1):8-15
pubmed: 11244452
Front Endocrinol (Lausanne). 2021 Apr 13;12:652444
pubmed: 33927694
Handb Exp Pharmacol. 2019;251:107-123
pubmed: 29675580
Nat Rev Endocrinol. 2017 Jan;13(1):26-35
pubmed: 27616452
Nat Commun. 2021 Sep 6;12(1):5274
pubmed: 34489410
Rev Physiol Biochem Pharmacol. 2023;186:135-176
pubmed: 35915363
Magn Reson Imaging. 2019 May;58:135-142
pubmed: 30742901
Int J Obes (Lond). 2021 Mar;45(3):706-710
pubmed: 33414488
Cell. 2014 Jun 5;157(6):1279-1291
pubmed: 24906147
J Clin Med. 2021 Sep 23;10(19):
pubmed: 34640356
Diabetes Res Clin Pract. 2018 Jan;135:7-10
pubmed: 29097285
Front Endocrinol (Lausanne). 2022 Feb 28;13:804874
pubmed: 35295982
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1148-e1158
pubmed: 34677618
Adipocyte. 2014 Jan 1;3(1):63-6
pubmed: 24575372
Diabetes Res Clin Pract. 2020 Mar;161:108068
pubmed: 32044349
Cytokine. 2022 Sep;157:155952
pubmed: 35780711
Nat Med. 2021 Jan;27(1):58-65
pubmed: 33398160
J Endocr Soc. 2022 Sep 27;6(12):bvac151
pubmed: 36325536
Front Pediatr. 2022 Mar 24;10:869581
pubmed: 35402348
Sci Rep. 2017 Jun 22;7(1):4031
pubmed: 28642596
Int J Obes (Lond). 2015 Jan;39(1):121-9
pubmed: 24813368
Cell Metab. 2018 Nov 6;28(5):750-763.e6
pubmed: 30122557
Exp Mol Med. 2018 Sep 13;50(9):1-11
pubmed: 30213948
Int J Mol Sci. 2020 Sep 10;21(18):
pubmed: 32927882
Front Endocrinol (Lausanne). 2021 Mar 12;12:599134
pubmed: 33776911
Int J Obes (Lond). 2018 Apr;42(4):919-922
pubmed: 29081506
Science. 2022 Jun 17;376(6599):1343-1347
pubmed: 35709278
BMC Biol. 2008 Nov 12;6:49
pubmed: 19014478
FEBS J. 2020 May;287(10):2087-2104
pubmed: 32196931
J Immunol. 2018 Dec 15;201(12):3669-3676
pubmed: 30464051

Auteurs

Cristina Garcia-Beltran (C)

Research Institute Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Health Institute Carlos III, Madrid, Spain.

Artur Navarro-Gascon (A)

Biochemistry and Molecular Biomedicine Department, Biomedicine Institute, University of Barcelona, Barcelona, Spain.
Network Biomedical Research Center of Physiopathology of Obesity and Nutrition (CIBEROBN), Health Institute Carlos III, Madrid, Spain.

Abel López-Bermejo (A)

Department of Pediatrics, Dr. Josep Trueta Hospital, Girona, Spain.
Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain.

Tania Quesada-López (T)

Biochemistry and Molecular Biomedicine Department, Biomedicine Institute, University of Barcelona, Barcelona, Spain.
Network Biomedical Research Center of Physiopathology of Obesity and Nutrition (CIBEROBN), Health Institute Carlos III, Madrid, Spain.

Francis de Zegher (F)

Leuven Research and Development, University of Leuven, Leuven, Belgium.

Lourdes Ibáñez (L)

Research Institute Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Health Institute Carlos III, Madrid, Spain.

Francesc Villarroya (F)

Research Institute Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Biochemistry and Molecular Biomedicine Department, Biomedicine Institute, University of Barcelona, Barcelona, Spain.
Network Biomedical Research Center of Physiopathology of Obesity and Nutrition (CIBEROBN), Health Institute Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH